RA
RLAY icon

Royce & Associates’s Relay Therapeutics RLAY Stock Holding History

Royce & Associates’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-48,381
Closed -$315K – 899
2024
Q2 		$315K Buy
48,381
+34,159
+240% +$233K ﹤0.01% 820
2024
Q1 		$118K Sell
14,222
-17,803
-56% -$174K ﹤0.01% 850
2023
Q4 		$353K Buy
+32,025
New +$270K ﹤0.01% 815

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Royce & Associates's RLAY Position: Q3 2024 in Review

Royce & Associates sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 48,381 shares — an estimated $315K sold.

Royce & Associates first reported a position in RLAY in Q4 2023 and held it in 3 quarters. The position peaked at $353K in Q4 2023. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Royce & Associates reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royce & Associates sold 48,381 Relay Therapeutics shares in Q3 2024, an estimated $315K.
  • Royce & Associates first reported a position in Relay Therapeutics in Q4 2023 and held it in 3 quarters.
  • Royce & Associates's Relay Therapeutics position peaked at $353K in Q4 2023.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Royce & Associates's 13F filing for Q3 2024, filed 6 Nov 2024.